MA28268A1 - Composes et techniques de traitement de la dyslipidemie - Google Patents

Composes et techniques de traitement de la dyslipidemie

Info

Publication number
MA28268A1
MA28268A1 MA28999A MA28999A MA28268A1 MA 28268 A1 MA28268 A1 MA 28268A1 MA 28999 A MA28999 A MA 28999A MA 28999 A MA28999 A MA 28999A MA 28268 A1 MA28268 A1 MA 28268A1
Authority
MA
Morocco
Prior art keywords
compounds
methods
treating dyslipidemia
treating
dyslipidemia
Prior art date
Application number
MA28999A
Other languages
English (en)
Inventor
Guoqing Cao
Ana Maria Escribano
Maria Carmen Fernandez
Todd Fields
Douglas Linn Gernert
Christopher Lawrence Cioffi
Robert Jason Herr
Nathan Bryan Mantlo
De La Nava Eva Maria Martin
Herranz Ana Isabel Mateo
Daniel Ray Mayhugh
Xiaodong Wang
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA28268A1 publication Critical patent/MA28268A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/32—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems containing carbocyclic rings other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D225/00—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
    • C07D225/04—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D225/06—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Abstract

La présente invention concerne des composés représentés par /a formule I dans laquelle n, m, p, q, Y, R1 R2, R3, R4, R5, et R6 sont tels que définis dans les spécifications ainsi que des compositions pharmaceutiques et des techniques d'utilisation qui conviennent pour traiter l'artériosclérose et ses séquelles.
MA28999A 2003-10-08 2006-05-03 Composes et techniques de traitement de la dyslipidemie MA28268A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US50973603P 2003-10-08 2003-10-08

Publications (1)

Publication Number Publication Date
MA28268A1 true MA28268A1 (fr) 2006-11-01

Family

ID=34465112

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28999A MA28268A1 (fr) 2003-10-08 2006-05-03 Composes et techniques de traitement de la dyslipidemie

Country Status (25)

Country Link
US (1) US7749992B2 (fr)
EP (2) EP2098512A1 (fr)
JP (1) JP4773969B2 (fr)
KR (1) KR20060085675A (fr)
CN (1) CN1863778A (fr)
AT (1) ATE442358T1 (fr)
AU (1) AU2004282101A1 (fr)
BR (1) BRPI0414186A (fr)
CA (1) CA2537942A1 (fr)
CY (1) CY1110537T1 (fr)
DE (1) DE602004023100D1 (fr)
DK (1) DK1670768T3 (fr)
EA (1) EA200600737A1 (fr)
EC (1) ECSP066484A (fr)
ES (1) ES2332051T3 (fr)
HR (1) HRP20090581T1 (fr)
IL (1) IL173819A0 (fr)
MA (1) MA28268A1 (fr)
MX (1) MXPA06003927A (fr)
NO (1) NO20062074L (fr)
PL (1) PL1670768T3 (fr)
PT (1) PT1670768E (fr)
SI (1) SI1670768T1 (fr)
WO (1) WO2005037796A1 (fr)
ZA (1) ZA200602888B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007530550A (ja) * 2004-03-26 2007-11-01 イーライ リリー アンド カンパニー 異脂肪血症を治療するための化合物および方法
JP2008504266A (ja) 2004-06-24 2008-02-14 イーライ リリー アンド カンパニー 異脂肪血症を治療するための化合物及び方法
US7652023B2 (en) * 2005-11-23 2010-01-26 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
US7790770B2 (en) * 2005-11-23 2010-09-07 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
TWI450896B (zh) * 2009-06-30 2014-09-01 Lilly Co Eli 反式－４－〔〔（５ｓ）－５－〔〔〔３，５－雙（三氟甲基）苯基〕甲基〕（２－甲基－２ｈ－四唑－５－基）胺基〕－２，３，４，５－四氫－７，９－二甲基－１ｈ－１－苯并氮呯－１－基〕甲基〕－環己基羧酸
CN103833636B (zh) * 2014-03-31 2015-09-02 武汉武药制药有限公司 一种莫扎伐普坦中间体的合成方法
EA039412B1 (ru) * 2015-07-31 2022-01-25 Арена Фармасьютикалз, Инк. 5-ht2c рецепторные агонисты и композиции и способы применения
CN110291383B (zh) * 2017-02-23 2021-12-28 株式会社Ihi Oh自由基检测探测器、oh自由基测定装置以及oh自由基测定方法
AR116798A1 (es) 2018-10-24 2021-06-16 VIIV HEALTHCARE UK Nº 5 LTD Inhibidores de la replicación del virus de la inmunodeficiencia humana
MX2022012881A (es) 2020-04-15 2022-11-08 Viiv Healthcare Uk No 5 Ltd Inhibidores de replicacion del virus de inmunodeficiencia humana.
CN113636977B (zh) * 2021-09-01 2022-12-20 温州大学 2-芳基苯并氮杂卓及其衍生物的合成方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2905909B2 (ja) * 1991-04-19 1999-06-14 大塚製薬株式会社 バソプレシン拮抗剤
TW270927B (fr) * 1992-10-16 1996-02-21 Otsuka Pharma Co Ltd
US5484783A (en) * 1994-03-24 1996-01-16 Merrell Dow Pharmaceuticals Inc. Hypocholesterolemic, antiatherosclerotic and hypotriglyceridemic mercaptoacetylamide and benzazapine derivatives
CA2184696C (fr) * 1994-03-24 2001-01-02 Gary A. Flynn Derives aminoacetylmercapto ayant des proprietes hypocholesterolemiques, antiatherosclereuses et hypotriglyceridemiques
ATE239710T1 (de) * 1994-06-15 2003-05-15 Otsuka Pharma Co Ltd Benzoheterocyclische derivate verwendbar als vasopressin- oder oxytocin-modulatoren
GB9523526D0 (en) * 1995-11-17 1996-01-17 Zeneca Ltd Therapeutic compounds
JPH09214746A (ja) 1996-02-02 1997-08-15 Ricoh Co Ltd 画像出力システム及び画像形成装置
DE19627431A1 (de) 1996-07-08 1998-01-15 Bayer Ag Heterocyclisch kondensierte Pyridine
HRP970330B1 (en) 1996-07-08 2004-06-30 Bayer Ag Cycloalkano pyridines
DE19627430A1 (de) 1996-07-08 1998-01-15 Bayer Ag Bicyclisch kondensierte Pyridine
US6207671B1 (en) 1996-07-08 2001-03-27 Bayer Aktiengesellschaft Cycloalkano-pyridines
US6333349B1 (en) * 1997-02-26 2001-12-25 Aventis Pharma Deutschland Gmbh Sulfonamide-substituted fused 7-membered ring compounds, their use as a medicament, and pharmaceutical preparations comprising them
DE19709125A1 (de) 1997-03-06 1998-09-10 Bayer Ag Substituierte Chinoline
JPH10287662A (ja) 1997-04-08 1998-10-27 Kitasato Inst:The Ｆｏ−５６３７ａ物質及びｂ物質並びにそれらの製造法
JP2959765B2 (ja) * 1997-12-12 1999-10-06 日本たばこ産業株式会社 ３−ピペリジル−４−オキソキナゾリン誘導体及びそれを含有してなる医薬組成物
US6147090A (en) * 1998-09-17 2000-11-14 Pfizer Inc. 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
US6147089A (en) * 1998-09-17 2000-11-14 Pfizer Inc. Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
GT199900147A (es) * 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
CO5271716A1 (es) 1999-11-30 2003-04-30 Pfizer Prod Inc Cristales de 4- carboxamino 1,2,3,4-tetrahidroquinolina 2- sustituida
HN2000000203A (es) 1999-11-30 2001-06-13 Pfizer Prod Inc Procedimiento para la obtencion de 1,2,3,4-tetrahidroquinolinas 4-carboxiamino-2- sustituidas.
US6664522B2 (en) * 2000-03-30 2003-12-16 Homer L. Spencer Method and apparatus for sealing multiple casings for oil and gas wells
US7115279B2 (en) * 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
HU225777B1 (en) * 2001-04-30 2007-08-28 Pfizer Prod Inc Compounds useful as intermediates for 4-aminoquinoline derivatwes and process for producing them
IL158765A0 (en) * 2001-06-21 2004-05-12 Pfizer Prod Inc Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors
DE10148436A1 (de) 2001-10-01 2003-04-17 Bayer Ag Tetrahydrochinoline
RU2004123637A (ru) 2002-02-01 2005-04-20 Пфайзер Продактс Инк. (Us) Фармацевтические лекарственные формы контролируемого высвобождения ингибитора транспортного белка холестерилового
CA2491426A1 (fr) 2002-07-01 2004-01-08 Surface Specialties, S.A. Precurseurs de polymeres hydrodiluables, leur preparation et leur utilisation
SI1533292T1 (sl) 2002-08-30 2007-08-31 Japan Tobacco Inc Dibenzilaminska spojina in njena medicinska uporaba
PL376156A1 (en) * 2002-10-04 2005-12-27 Millennium Pharmaceuticals, Inc. Pgd2 receptor antagonists for the treatment of inflammatory diseases
WO2004078730A2 (fr) 2003-03-04 2004-09-16 Takasago International Corporation Procede de production d'amines optiquement actives
US20040204450A1 (en) * 2003-03-28 2004-10-14 Pfizer Inc Quinoline and quinoxaline compounds
EP1670765A2 (fr) 2003-09-30 2006-06-21 Pfizer Products Inc. Inhibiteurs de la proteine de transfert d'ester de cholesteryle (cetp) et leurs metabolites
JP2007530550A (ja) * 2004-03-26 2007-11-01 イーライ リリー アンド カンパニー 異脂肪血症を治療するための化合物および方法
JP2008504266A (ja) * 2004-06-24 2008-02-14 イーライ リリー アンド カンパニー 異脂肪血症を治療するための化合物及び方法

Also Published As

Publication number Publication date
JP2007508301A (ja) 2007-04-05
ES2332051T3 (es) 2010-01-25
SI1670768T1 (sl) 2010-01-29
US20070254869A1 (en) 2007-11-01
DK1670768T3 (da) 2009-11-09
EP2098512A1 (fr) 2009-09-09
JP4773969B2 (ja) 2011-09-14
EP1670768A1 (fr) 2006-06-21
CN1863778A (zh) 2006-11-15
AU2004282101A1 (en) 2005-04-28
MXPA06003927A (es) 2008-02-07
US7749992B2 (en) 2010-07-06
PT1670768E (pt) 2009-11-20
CY1110537T1 (el) 2015-04-29
ZA200602888B (en) 2007-11-28
KR20060085675A (ko) 2006-07-27
HRP20090581T1 (hr) 2009-12-31
BRPI0414186A (pt) 2006-10-31
PL1670768T3 (pl) 2010-01-29
ATE442358T1 (de) 2009-09-15
NO20062074L (no) 2006-05-08
CA2537942A1 (fr) 2005-04-28
WO2005037796A1 (fr) 2005-04-28
IL173819A0 (en) 2006-07-05
ECSP066484A (es) 2006-10-10
EP1670768B1 (fr) 2009-09-09
DE602004023100D1 (de) 2009-10-22
EA200600737A1 (ru) 2006-10-27

Similar Documents

Publication Publication Date Title
MA28268A1 (fr) Composes et techniques de traitement de la dyslipidemie
CY1110398T1 (el) Ενωσεις για την αγωγη της δυσλιπιδαιμιας
SE0301373D0 (sv) Novel compounds
ATE433447T1 (de) Pyrimiidinverbindungen
NO20056192L (no) Kapaseinhibitorer og anvendelse derav
SE0302811D0 (sv) Novel compounds
DE602004019548D1 (de) Kondensierte heterocyclen als inhibitoren von glutamatracemase (muri)
SE0301446D0 (sv) New Compounds
NO20054361D0 (no) Benzensylfonamidderivater, fremgangsmate for fremstilling og anvendelse derav for behandlig av smerte
PL376324A1 (en) Piperazinyl and diazapanyl benzamides and benzthioamides
PA8573501A1 (es) Derivados de benzoxazina y su empleo
SE0303541D0 (sv) New compounds
NO20060718L (no) Substituerte tiofoner og deres anvendelse
DE602004031410D1 (de) Inden derivate als pharmazeutika
SE0303280D0 (sv) Novel compounds
ATE335739T1 (de) Cak inhibitoren und deren verwendungen
UY29012A1 (es) "oxazolididonas y composiciones y metodos relacionados"
SE0302755D0 (sv) Novel compounds
NO20053562L (no) Nye aminobenzofenonforbindelser
SE0301697D0 (sv) Novel fused heterocycles and uses thereof